Finance

Lists
TMAN:BKK
T Man Pharmaceutical PCL
฿10,40
0,00%
(0,00) 1D
14 Okt., 16:40:00 GMT+7  ·   THB
All symbols
SymbolPriceChange% Change
Generating top insights for TMAN...
Open
฿10,50
High
฿10,50
Low
฿10,30
Mkt. cap
4,16 mjd
Avg. vol.
342,82 k
Volume
86,23 k
Dividend
5,38%
Quarterly dividend
฿0,14
Ex-dividend date
26 Aug. 2026
P/E ratio
8,24
52-wk high
฿13,60
52-wk low
฿9,95
EPS
฿1,26
Shares outstanding
400,00 m
No. of employees
1 k
Open
฿10,50
High
฿10,50
Low
฿10,30
Mkt. cap
4,16 mjd
Avg. vol.
342,82 k
Volume
86,23 k
Dividend
5,38%
Quarterly dividend
฿0,14
Ex-dividend date
26 Aug. 2026
P/E ratio
8,24
52-wk high
฿13,60
52-wk low
฿9,95
EPS
฿1,26
Shares outstanding
400,00 m
No. of employees
1 k
News stories
From web sources and news partners
About T Man Pharmaceutical PCL
CEO-
Employees1,05 k
Founded1972
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in THB
Loading Previous Earnings...
Revenue
Net income
All values in THB
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
661,41 m
730,15 m
633,71 m
594,36 m
Cost of goods sold
377,69 m
392,07 m
338,37 m
321,04 m
Cost of revenue
377,69 m
392,07 m
338,37 m
321,04 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
143,41 m
175,59 m
151,39 m
155,05 m
Operating expense
145,32 m
177,27 m
150,88 m
151,66 m
Total operating expenses
523,02 m
569,34 m
489,25 m
472,70 m
Operating income
138,40 m
160,81 m
144,46 m
121,66 m
Other non operating income
-
-
-
-
EBT including unusual items
131,64 m
212,45 m
139,82 m
118,02 m
EBT excluding unusual items
131,64 m
155,00 m
139,82 m
118,02 m
Income tax expense
19,04 m
30,67 m
25,18 m
20,44 m
Effective tax rate
14,47%
14,44%
18,01%
17,32%
Other operating expenses
-
-
-
-
Net income
112,60 m
181,79 m
114,63 m
97,58 m
Net profit margin
17,02%
24,90%
18,09%
16,42%
Earnings per share
-
0,46
0,29
-
Interest and investment income
-
-
-
-
Interest expense
-6,76 m
-5,81 m
-4,64 m
-3,64 m
Net interest expenses
-6,76 m
-5,81 m
-4,64 m
-3,64 m
Depreciation and amortization charges
-
-
-
-
EBITDA
168,50 m
185,85 m
182,21 m
158,76 m
Gain or loss from assets sale
-
-195,74 k
-
-
AI content may include mistakes. Learn more
Google-programme